ClinicalTrialsFinder
RecruitingNCT05461430

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance

Sponsor

Travera Inc

Enrollment

200 participants

Start Date

Jul 15, 2022

Study Type

OBSERVATIONAL

Conditions

Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small Cell

Summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patient is ≥18 years of age
  • Written Informed Consent provided by patient
  • Diagnosis of any kind of carcinoma
  • Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
  • Proceeding onto therapy for treatment
  • Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion Criteria2

  • Lack of informed consent
  • Unable to obtain sufficient sample

Locations(1)

xCures

Oakland, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05461430

Related Trials

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

NCT064564111 location

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT0345277468 locations

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT0559262632 locations

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

NCT063582221 location

First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.

NCT069464981 location